Summary:
- GSK, a leading pharmaceutical company, has announced plans to acquire efimosfermin, a potential best-in-class specialty medicine to treat and prevent the progression of steatotic liver disease (SLD).
- Efimosfermin is a Phase III-ready drug that has shown promising results in clinical trials for improving liver health and reducing the risk of advanced liver disease, including non-alcoholic steatohepatitis (NASH).
- This acquisition aligns with GSK's strategy to expand its portfolio of specialty medicines and strengthen its capabilities in addressing complex liver conditions, which can have significant health implications if left untreated.